Send to:

Choose Destination
See comment in PubMed Commons below
Parasitology. 2014 Jan;141(1):140-6. doi: 10.1017/S003118201300142X. Epub 2013 Aug 28.

Screening strategies to identify new chemical diversity for drug development to treat kinetoplastid infections.

Author information

  • 1Drugs for Neglected Diseases initiative, 15 Chemin Louis-Dunant, 1202 Geneva, Switzerland.

Erratum in

  • Parasitology. 2014 Jan;141(1):147.


The Drugs for Neglected Diseases initiative (DNDi) has defined and implemented an early discovery strategy over the last few years, in fitting with its virtual R&D business model. This strategy relies on a medium- to high-throughput phenotypic assay platform to expedite the screening of compound libraries accessed through its collaborations with partners from the pharmaceutical industry. We review the pragmatic approaches used to select compound libraries for screening against kinetoplastids, taking into account screening capacity. The advantages, limitations and current achievements in identifying new quality series for further development into preclinical candidates are critically discussed, together with attractive new approaches currently under investigation.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Cambridge University Press
    Loading ...
    Write to the Help Desk